Stepan Company (SCL) SEC Filings & Earnings Calls
EquiReason read 12 Stepan Company SEC filings in the last 12 months. Latest: 8-K on 2026-09-28 — Stepan Company entered into a new $500M credit agreement ($350M revolver + $150M term loan) maturing 2031, replacing existing $350M revolver and $100M term loan. Includes $250M exp.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- 2.5%
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
28 Sep 20268-K · 1.01, 2.03Stepan Company entered into a new $500M credit agreement ($350M revolver + $150M term loan) maturing 2031, replacing existing $350M revolver and $100M term loan. Includes $250M expansion option.open
Figures in the filing · each found in the filing text
| credit_facility_amount · 2026-09-25 | $500M |
Risks flagged
Covenants include interest coverage and net leverage ratios; default events could accelerate repayment.
“Requires maintenance of certain interest coverage and net leverage financial ratios and compliance with certain other covenants.”
5 Aug 202610-QStepan Company reported strong Q2 2026 results with revenue up 15% YoY and operating income up 107% YoY, driven by pricing actions and volume growth.earningsopen
Figures in the filing · each found in the filing text
| Net Income · Q2-2026 | $23M | +103% y/y |
| Adjusted Net Income · Q2-2026 | $27M | +126% y/y |
| Adjusted EBITDA · Q2-2026 | $74M | +45% y/y |
| Cash and Cash Equivalents · 2026-06-30 | $114M | |
| Total Debt · 2026-06-30 | $647M |
Risks flagged
Restructuring Execution Risk
“The Company recognized $5.1 million and $70.5 million of pre-tax business restructuring expense related to these asset shutdowns during the second quarter and the first six months of 2026, respectively.” · word for word
Geopolitical and Supply Uncertainty
“The Company believes a portion of the volume growth reflects customer pre-buying in response to geopolitical and product supply uncertainty.” · word for word
29 Jul 20268-K · 2.02, 2.05, 5.02, 8.01Q2 2026 net income up 102% YoY to $22.9M; Adjusted EBITDA up 45% to $74.4M. Also announced workforce reduction of ~100 roles as part of restructuring plan.earningsopen
Figures in the filing · each found in the filing text
| Net income · Q2-2026 | $23M | +102% y/y |
| Adjusted EBITDA · Q2-2026 | $74M | +45% y/y |
| Organic sales volume growth · Q2-2026 | 6.0% | |
| Free cash flow (excluding working capital) · Q2-2026 | $33M | +69% y/y |
Risks flagged
Restructuring charges of $75-80M for FY2026; cash impact $14-18M.
“The Company anticipates recognizing full-year restructuring charges in the range of $75.0 million to $80.0 million in connection with Project Catalyst.” · word for word
Free cash flow negative $15.0M due to higher working capital requirements.
“Free cash flow for the quarter was a negative $15.0 million, driven by higher working capital requirements.”
6 May 202610-QNet Income (Loss) $-41M; Adjusted EBITDA $50M (-14% y/y); Cash and Cash Equivalents $141M; Guidance: FY2026 capex guided $105M-$115M; no revenue or earnings guidance providedopen
Figures in the filing · each found in the filing text
| Net Income (Loss) · Q1-2026 | $-41M | |
| Adjusted EBITDA · Q1-2026 | $50M | -14% y/y |
| Cash and Cash Equivalents · 2026-03-31 | $141M |
Guidance
FY2026 capex guided $105M-$115M; no revenue or earnings guidance provided
No explicit revenue or earnings guidance; capex guidance maintained; restructuring indicates management is proactively addressing cost structure.
Risks flagged
Restructuring execution risk
“The Company recognized $65.4 million of pre-tax business restructuring expense related to these asset shutdowns during the first quarter of 2026.” · word for word
Competitive pressure in Latin America
“The lower average unit margins largely reflect increased competitive pressures in Mexico.” · word for word
European construction demand weakness
“The lower sales volume is due to lower construction demand related to the macroeconomic environment and economic uncertainties along with increased competitive activity.” · word for word
28 Apr 20268-K · 2.02, 8.01Net Sales $605M (+2% y/y); Net Income (Loss) $-41M; Adjusted Net Income $10M (-47% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q1-2026 | $605M | +2% y/y |
| Net Income (Loss) · Q1-2026 | $-41M | |
| Adjusted Net Income · Q1-2026 | $10M | -47% y/y |
| Adjusted EBITDA · Q1-2026 | $50M | -14% y/y |
| Specialty Products Adjusted EBITDA · Specialty Products · Q1-2026 | $6M | -11% y/y |
Risks flagged
Restructuring execution risk and potential operational disruptions from site closures.
“We are executing Project Catalyst safely and in line with expectations despite early quarter weather-related impacts and the new geopolitical challenges.” · word for word
Higher oleochemicals raw material costs and competitive pressures in Mexico impacting Surfactants margins.
“Surfactants EBITDA was down due to higher oleochemicals prices, the cold snap in the U.S., production timing differences in Asia along with competitive pressures in Mexico.” · word for word
European Polymers demand weakness persists with 19% volume decline.
“Sales volume decreased 6% in the quarter. North American sales volume was up 5% but this was more than offset by a 19% decline in Europe.” · word for word
25 Mar 2026DEF 14AAnnual proxy statement filed, detailing executive compensation, financial results, and governance matters for FY2025.open
Figures in the filing · each found in the filing text
| Net Income · FY2025 | $47M | -7% y/y |
| Adjusted Net Income · FY2025 | $42M | -17% y/y |
| Diluted EPS · FY2025 | $2.05 | -7% y/y |
| Adjusted Diluted EPS · FY2025 | $1.82 | -17% y/y |
| Surfactants Operating Income · Surfactants · FY2025 | $67M | -21% y/y |
| Polymers Operating Income · Polymers · FY2025 | $43M | +7% y/y |
| Specialty Products Operating Income · Specialty Products · FY2025 | $26M | +23% y/y |
| Dividends Paid · FY2025 | $35M | |
| EBITDA · FY2025 | $208M | |
| Free Cash Flow · FY2025 | $27M |
Risks flagged
Surfactant segment earnings decline
“The Surfactant segment delivered operating income of $67.4 million, a 21% decrease versus prior year.” · word for word
26 Feb 202610-KRecurring environmental costs $45M; Number of employees 2,328 (-3% y/y)open
Figures in the filing · each found in the filing text
| Recurring environmental costs · FY2025 | $45M | |
| Number of employees · 2025-12-31 | 2,328 | -3% y/y |
Risks flagged
Raw material and energy cost volatility
“The volatility of raw material, natural gas and electricity costs, as well as any disruption in their supply, may result in increased costs and materially and adversely affect the Company’s business, financial position, results of operations and cash flows.” · word for word
1,4 dioxane regulatory risk
“These trends and corresponding changes in consumer preferences could reduce demand for our ethoxylated surfactant products, as our customers look to reduce the levels of ethoxylated surfactants in their finished products to stay below the maximum allowed levels or transition to alternative surfactants with lower levels of 1,4 dioxane.” · word for word
Operational disruption from natural disasters
“For example, in 2024, the operations of the Company’s Elwood, Illinois (Millsdale) facility were negatively affected by a flood event.” · word for word
Geopolitical risk affecting supply chain
“For example, recent conflicts in the Middle East region have contributed to increased shipping costs and transportation times for certain raw materials and products.” · word for word
23 Feb 20268-K · 2.02, 8.01Net Sales $554M (+5% y/y); Net Income $5M (+49% y/y); Adjusted Net Income $-531,000.00 (-119% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q4-2025 | $554M | +5% y/y |
| Net Income · Q4-2025 | $5M | +49% y/y |
| Adjusted Net Income · Q4-2025 | $-531000.00 | -119% y/y |
| EBITDA · Q4-2025 | $43M | +21% y/y |
| Adjusted EBITDA · Q4-2025 | $34M | -3% y/y |
| Free Cash Flow · Q4-2025 | $25M | |
| Global Sales Volume Change · Q4-2025 | -3.0% | |
| Surfactant Net Sales · Surfactants · Q4-2025 | $402M | +6% y/y |
| Polymers Net Sales · Polymers · Q4-2025 | $132M | +1% y/y |
| Specialty Products Net Sales · Specialty Products · Q4-2025 | $20M | +20% y/y |
Risks flagged
Surfactant volume decline due to lower demand in commodity Laundry & Cleaning end markets indicates consumer demand slowdown.
“Surfactant sales volume declined 7% year-over-year primarily due to lower demand within the commodity Laundry & Cleaning end markets.”
Higher interest expense from lower capitalized interest due to Pasadena site start-up.
“Higher interest expense, resulting from lower capitalized interest income recognition due to the Pasadena, TX site start-up.” · word for word
23 Feb 20268-K · 2.05, 7.01Stepan approved Project Catalyst, a restructuring plan to close Fieldsboro site and decommission assets, targeting $100M pre-tax savings over two years with $70-80M charges in 2026.open
Risks flagged
Restructuring execution risk and potential operational disruption from site closures and asset decommissioning.
“Closure of Fieldsboro site and decommissioning of assets at Elwood and Stalybridge facilities by mid-2026.”
Continued demand weakness in commodity surfactants may persist, impacting revenue.
“Site closure driven by continued lower demand in commodity surfactants.”
28 Nov 20258-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Severance plan could increase costs in case of executive departures or change in control.
“Cash severance in an amount equal to (i) the sum of the Executive’s base salary plus target annual bonus multiplied by (ii) the number of months in the Severance Period” · word for word
5 Nov 202510-QStepan reported Q3 2025 net income down 54% YoY due to surfactant margin compression and higher start-up costs, despite 8% revenue growth.earningsopen
Figures in the filing · each found in the filing text
| Net income · Q3-2025 | $11M | -54% y/y |
| Adjusted net income · Q3-2025 | $11M | -54% y/y |
| EBITDA · Q3-2025 | $56M | +6% y/y |
Guidance
Capital expenditure estimate $118M-$123M for 2025
No explicit earnings guidance provided; capital expenditure estimate maintained for 2025.
Risks flagged
Raw material cost volatility
“The lower average unit margins negatively impacted the year-over-year change in gross profit by $5.7 million and were primarily attributable to higher expenses associated with the start-up of the Company's new alkoxylation facility in Pasadena, Texas and higher oleochemical raw material costs.” · word for word
New facility start-up costs
“higher expenses associated with the start-up of the Company's new alkoxylation facility in Pasadena, Texas” · word for word
Pharmaceutical order timing volatility
“This increase was primarily due to higher sales volume that was driven by order timing fluctuations within the pharmaceutical business.” · word for word
29 Oct 20258-K · 8.01Quarterly cash dividend per share $0.40open
Figures in the filing · each found in the filing text
| quarterly cash dividend per share · Q4-2025 | $0.40 |
Stepan Company — questions
- What did Stepan Company file recently?
- 12 SEC filings in the last 12 months. Latest: 8-K on 2026-09-28 — Stepan Company entered into a new $500M credit agreement ($350M revolver + $150M term loan) maturing 2031, replacing existing $350M revolver and $100M term loan. Includes $250M expansion option.
Every figure on this page comes from Stepan Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.